Overview ATAC - Bone Density Sub-Protocol Status: Completed Trial end date: 2007-04-01 Target enrollment: Participant gender: Summary To assess and quantify the changes in bone mineral density between the ARIMIDEX and ARIMIDEX plus NOLVADEX groups when compared to the NOLVADEX alone treatment group whilst receiving trial therapy. Phase: Phase 3 Details Lead Sponsor: AstraZenecaTreatments: AnastrozoleTamoxifen